IP Library Granted Patent US 7,918,010
Granted Patent B2
US 7,918,010 · App. 12/544,656 · Granted Apr 5, 2011

Method for making a radiopharmaceutical pig

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,918,010
App. No.
12/544,656
Granted
Apr 5, 2011
Kind
B2
Abstract

A pharmaceutical pig is used to transport a syringe containing a liquid radiopharmaceutical from a radiopharmacy to a medical facility for administration to a patient. The pharmaceutical pig includes an elongate polymer cap that is removably attached to an elongate polymer base. The elongate polymer cap includes a cap shell that completely encloses a cap shielding element and the elongate polymer base includes a base shell that completely encloses a base shielding element. Preferably the polymer utilized for the cap shell and the base shell is polycarbonate resin, e.g., LEXAN®. An inner liner is not utilized and the cap shielding element and the base shielding element, which are preferably, but not necessarily, made of lead, are completely sealed and unexposed.

Claims (28)

1. A method for making a radiopharmaceutical pig comprising:

forming a shielding element of nuclear shielding material to have an open top, a closed bottom, a wall extending between the top and bottom, an inner surface, an outer surface, and an interior cavity;

placing the shielding element into an injection molding machine;

injecting a polymer material into the molding machine so that an entirety of the shielding element including, but not limited to, the inner surface and outer surface, thereof, is completely covered by the polymer material; and

allowing the polymer material to harden.

2. The method set forth in claim 1 wherein the polymer material comprises polycarbonate resin.

3. The method set forth in claim 1 wherein forming a shielding element of nuclear shielding material comprises pouring molten nuclear shielding material into a mold and allowing it to solidify.

4. The method set forth in claim 3 wherein pouring molten nuclear shielding material into a mold comprises pouring molten lead into the mold.

5. The method set forth in claim 1 wherein forming a shielding element of nuclear shielding material comprises forming a base shielding element.

6. The method set forth in claim 1 wherein forming a shielding element of nuclear shielding material comprises forming a cap shielding element.

7. A method for making a radiopharmaceutical pig comprising:

forming a base shielding element of nuclear shielding material to have an open top, a closed bottom, a wall extending between the top and bottom, an inner surface, an outer surface, and an interior cavity;

placing the base shielding element into an injection molding machine;

injecting a polymer material into the molding machine so that an entirety of the base shielding element including, but not limited to, the inner surface and the outer surface thereof is completely covered by the polymer material;

allowing the polymer material covering the entirety of the base shielding element to harden;

forming a cap shielding element of nuclear shielding material to have an open top, a closed bottom, a wall extending between the top and bottom, an inner surface, an outer surface, and an interior cavity;

placing the cap shielding element into an injection molding machine;

injecting a polymer material into the molding machine so that an entirety of the cap shielding element including, but not limited to, the inner surface and outer surface thereof is completely covered by the polymer material;

allowing the polymer material covering an entirety of the cap shielding element to harden; and

coupling the cap shielding element to the base shielding element.

8. The method set forth in claim 7 wherein the polymer material that covers an entirety of the cap shielding element comprises polycarbonate resin.

9. The method set forth in claim 8 wherein the polymer material that covers an entirety of the base shielding element comprises polycarbonate resin.

10. The method set forth in claim 9 wherein the nuclear shielding material of the base shielding element comprises lead.

11. The method set forth in claim 10 wherein the nuclear shielding material of the cap shielding element comprises lead.

12. The method set forth in claim 7 wherein forming a base shielding element of a nuclear shielding material comprises pouring molten nuclear shielding material into a mold and allowing it to solidify.

13. The method set forth in claim 12 wherein pouring molten nuclear shielding material into a mold comprises pouring molten lead into the mold.

14. The method set forth in claim 7 wherein forming a cap shielding element of nuclear shielding material comprises pouring molten material into a mold and allowing it to solidify.

15. The method set forth in claim 14 wherein pouring molten material into a mold comprises pouring molten lead into the mold.

Assignments (2)
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 032480, FRAME 0001 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: THERAKOS, INC.; MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065609/0322 →
SECURITY INTEREST Recorded Mar 19, 2014
From: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS INC.; MALLINCKRODT CARIBBEAN, INC.; MALLINCKRODT US POOL LLC; MALLINCKRODT INC.; LUDLOW CORPORATION; CNS THERAPEUTICS, INC.; ENTERPRISES HOLDINGS, INC.; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS, INC; MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC; MALLINCKRODT ENTERPRISES HOLDINGS, INC.
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 032480/0001 →